Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 19/20 | 0.78 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.46 |
| ▸ | PIK3R2 | O00459 | 7/20 | 0.46 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12813117 | 0.91 | PIK3CD (0.65) | PIK3CDPIK3CGPIK3R2BCL2PIK3CB | |
| SCHEMBL12813127 | 0.89 | PIK3CD (0.72) | PIK3CDPIK3CGPIK3R2BCL2PIK3CB | |
| SCHEMBL12813059 | 0.88 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3R2PIK3CBPIK3R1 | |
| SCHEMBL9929022 | 0.86 | PIK3CD (0.59) | PIK3CDPIK3CGPIK3R2BCL2 | |
| SCHEMBL15487844 | 0.83 | PIK3CD (0.66) | PIK3CDPIK3CGPIK3R2BCL2PIK3CB | |
| SCHEMBL12813249 | 0.83 | PIK3CD (0.66) | PIK3CDPIK3CGPIK3R2BCL2PIK3CB | |
| Trifluoroacetic Acid SCHEMBL12812979 | 0.82 | PIK3CD (0.88) | PIK3CDPIK3CGPIK3R2PIK3CBPIK3R1 | |
| SCHEMBL12813125 | 0.81 | PIK3CD (0.66) | PIK3CDPIK3CGPIK3R2PIK3CBPIK3CA | |
| SCHEMBL12813132 | 0.81 | PIK3CD (0.81) | PIK3CDPIK3CGPIK3R2PIK3CBPIK3CA | |
| SCHEMBL15488286 | 0.81 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3R2BCL2PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126948-B2 | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-09-08 | — | — | US | claimed |
| US-20140057912-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-02-27 | — | — | US | claimed |
| WO-2012135009-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-10-04 | — | — | WO | claimed |
| US-9126948-B2 | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140057912-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057912-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 4/4885PIK3R2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.